Login to Your Account



Oversubscribed series C brings in $59M, adds U.S. investors to Hookipa

By Nuala Moran
Staff Writer

Monday, December 11, 2017

LONDON – Hookipa Biotech AG has raised €50 million (US$59 million) in an oversubscribed series C, providing the means to advance clinical development of its vaccines technologies in both infectious diseases and cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription